OPEN-LABEL COMPARISON OF OLANZAPINE LONG-ACTING INJECTION AND ORAL OLANZAPINE: A 2-YEAR, RANDOMIZED STUDY IN OUTPATIENTS WITH SCHIZOPHRENIA

被引：0
|
作者：
Detke, Holland C. [1 ]
Weiden, Peter J. [2 ]
Llorca, P. M. [3 ]
Choukour, M. [4 ]
Watson, Susan B. [1 ]
Brunner, E. [1 ]
Ascher-Svanum, H. [1 ]
机构：
[1] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[2] Univ Illinois, Dept Psychiat, Chicago, IL 60612 USA
[3] Ctr Hosp Univ, Psychiat Serv, Clermont Ferrand, France
[4] i3 Statprobe, Med Writing & Sci Commun, San Diego, CA USA
来源：
SCHIZOPHRENIA BULLETIN | 2011年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
引用
收藏
页码：300 / 300
页数：1
相关论文
共 50 条
  • [21] Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine (vol 26, pg 422, 2011)
    McDonnell, D. P.
    Kryzhanovskaya, L. A.
    Zhao, F.
    Detke, H. C.
    Feldman, P. D.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (07) : 536 - 536
  • [22] Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia
    Faries, Douglas E.
    Ascher-Svanum, Haya
    Nyhuis, Allen W.
    Kinon, Bruce J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) : 1399 - 1405
  • [23] Olanzapine Long-Acting Injection A Review of its Use in the Treatment of Schizophrenia
    Frampton, James E.
    DRUGS, 2010, 70 (17) : 2289 - 2313
  • [24] Single- and Multiple-Dose Pharmacokinetic, Safety, and Tolerability Profiles of Olanzapine Long-Acting Injection: An Open-Label, Multicenter, Nonrandomized Study in Patients With Schizophrenia
    Mitchell, Malcolm
    Kothare, Prajakti
    Bergstrom, Richard
    Zhao, Fangyi
    Jen, Kai Yu
    Walker, Daniel
    Johnson, Jason
    McDonnell, David
    CLINICAL THERAPEUTICS, 2013, 35 (12) : 1890 - 1908
  • [25] Efficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophrenia
    Detke, H.
    McDonnell, D.
    Kane, J.
    Naber, D.
    Sethuraman, G.
    Lin, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S393 - S394
  • [26] Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
    Citrome, Leslie
    PATIENT PREFERENCE AND ADHERENCE, 2009, 3 : 345 - 355
  • [27] An open-label study of olanzapine in the first episode of schizophrenia in adolescents
    Dabokowska, M
    EUROPEAN PSYCHIATRY, 2002, 17 : 115S - 115S
  • [28] Olanzapine long-acting injection: When and for how long is oral supplementation required?
    Chew, Majella Su-Xian
    Dhillon, Rohan
    Tibrewal, Prashant
    Narang, Birinder
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2013, 47 (12): : 1214 - 1215
  • [29] An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia
    Mozes, Tamar
    Ebert, Tanya
    Michal, Sabbagh-Etun
    Spivak, Baruch
    Weizman, Abraham
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2006, 16 (04) : 393 - 403
  • [30] Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
    Tatiana Dilla
    Jörgen Möller
    Paul O’Donohoe
    María Álvarez
    José A Sacristán
    Michael Happich
    Antje Tockhorn
    BMC Psychiatry, 14
12345